• Product Name:Lacosamide
  • Molecular Formula:C13H18N2O3
  • Purity:99%
  • Molecular Weight:250.298

Product Details:

CasNo: 175481-36-4

Molecular Formula: C13H18N2O3

Chinese Factory Supply 99% Pure Lacosamide 175481-36-4 Safe Transportation

  • Molecular Formula:C13H18N2O3
  • Molecular Weight:250.298
  • Vapor Pressure:1.4E-11mmHg at 25°C 
  • Melting Point:141-143?C 
  • Refractive Index:1.52 
  • Boiling Point:536.4 °C at 760 mmHg 
  • PKA:14.19±0.46(Predicted) 
  • Flash Point:278.2 °C 
  • PSA:67.43000 
  • Density:1.12 g/cm3 
  • LogP:1.23570 

Lacosamide(Cas 175481-36-4) Usage


Lacosamide (LCM), known by the brand name Vimpat, is an antiepileptic drug (AED) primarily used to treat partial-onset seizures in adults and children. It is a member of a series of functionalized amino acids synthesized specifically as an anticonvulsant or antiepileptic drug. Lacosamide reduces the spread of seizure activity in the brain by acting on the central nervous system (CNS).


Epilepsy: Adjunctive treatment of focal seizures with or without secondary generalization.


Partial-Onset Seizures: Lacosamide is primarily indicated for the treatment of focal (partial) seizures in adults and children. It is used either as monotherapy or in conjunction with other medications to reduce the number and severity of seizures.

Generalized Tonic-Clonic Seizures: In addition to partial-onset seizures, lacosamide is also used with other medicines to treat primary generalized tonic-clonic seizures.

Chemical Properties

White to Off-White Solid


Harris FRC (United States)

Brand name



175481-36-4 Relevant articles

Lacosamide as adjunctive therapy for partial-onset seizures: A randomized controlled trial

Steve Chung, Michael R. Sperling, Victor Biton, Gregory Krauss, David Hebert, G. David Rudd, Pamela Doty, on behalf of the SP754 Study Group

, Epilepsia, Volume51, Issue6 June 2010 Pages 958-967

This multicenter, double-blind, placebo-controlled trial randomized patients 1:2:1 to placebo, lacosamide 400 mg, or lacosamide 600 mg/day. After an 8-week baseline period, patients began treatment with placebo or lacosamide 100 mg/day, were force-titrated weekly (100 mg/day increments) to the target dose, and entered a 12-week maintenance period.

Current understanding of the mechanism of action of the antiepileptic drug lacosamide

Michael A. Rogawski a, Azita Tofighy b, H. Steve White c, Alain Matagne d, Christian Wolff d

, Epilepsy Research Volume 110, February 2015, Pages 189-205

The antiepileptic drug lacosamide [(R)-2-acetamido-N-benzyl-3-methoxypropanamide], a chiral functionalized amino acid, was originally identified by virtue of activity in the mouse and rat maximal electroshock (MES) test. Attention was drawn to lacosamide because of its high oral potency and stereoselectivity.

Direct, Enantioselective, and Nickel(II) Catalyzed Reactions of N-Azidoacetyl Thioimides with Trimethyl Orthoformate: A New Combined Methodology for the Rapid Synthesis of Lacosamide and Derivatives

Teloxa, Saul F.,Kennington, Stuart C. D.,Camats, Marc,Romea, Pedro,Urpí, Fèlix,Aullón, Gabriel,Font-Bardia, Mercè

, p. 11540 - 11548 (2020/08/10)

A direct and highly enantioselective rea...

175481-36-4 Upstream products

  • 171623-02-2


  • 74-88-4

    methyl iodide

  • 58685-35-1


  • 175481-29-5

    methyl α-acetamido-N-benzylmalonamate

175481-36-4 Downstream products

  • 175481-36-4


  • 175481-36-4


  • 262845-82-9


  • 1318767-66-6


Relevant Products